Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

New Zealand: These 32 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "New Zealand: These 32 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in New Zealand?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: New Zealand Patent 576,485
Patent Title: FUMARATE SALT OF (ALPHA S, BETA R)-6-BROMO-ALPHA-[2-(DIMETHYLAMINO)ETHYL]-2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-QUINOLINEETHANOL

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in New Zealand?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: New Zealand Patent 577,197

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in New Zealand?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: New Zealand Patent 577,004
Patent Title: 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in New Zealand?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: New Zealand Patent 569,197
Patent Title: Therapeutic compositions comprising ingenol angelate

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can LEXISCAN (regadenoson) generic drug versions launch in New Zealand?

Generic name: regadenoson
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 02, 2027
Generic Entry Controlled by: New Zealand Patent 570,239
Patent Title: Preparation of (1-{ 9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl} pyrazol-4-yl)-N-methylcarboxamide monohydrate

LEXISCAN is a drug marketed by Astellas. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LEXISCAN

See drug price trends for LEXISCAN.

The generic ingredient in LEXISCAN is regadenoson. Additional details are available on the regadenoson profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in New Zealand?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: New Zealand Patent 579,047
Patent Title: STABLE DIGESTIVE ENZYME COMPOSITIONS

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in New Zealand?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: New Zealand Patent 598,477
Patent Title: STABLE DIGESTIVE ENZYME COMPOSITIONS

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in New Zealand?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: New Zealand Patent 579,047
Patent Title: STABLE DIGESTIVE ENZYME COMPOSITIONS

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in New Zealand?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: New Zealand Patent 598,477
Patent Title: STABLE DIGESTIVE ENZYME COMPOSITIONS

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in New Zealand?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: New Zealand Patent 579,011
Patent Title: PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in New Zealand?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: New Zealand Patent 579,851
Patent Title: SOLID PHARMACEUTICAL COMPOSITION COMPRISING A BENZIMIDAZOLE-7-CARBOXYLATE DERIVATIVE AND A PH CONTROL AGENT

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. Additional details are available on the azilsartan kamedoxomil profile page.

When can INLYTA (axitinib) generic drug versions launch in New Zealand?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: New Zealand Patent 580,126

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in New Zealand?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: New Zealand Patent 571,803
Patent Title: Amide indole derivatives as modulators of ATP-binding cassette transporters

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in New Zealand?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: New Zealand Patent 596,889
Patent Title: Use of amide indole derivatives as modulators of ATP-binding cassette transporters

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in New Zealand?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: New Zealand Patent 611,485
Patent Title: Modulators of atp-binding cassette transporters

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in New Zealand?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: New Zealand Patent 580,888

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in New Zealand?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: New Zealand Patent 580,642

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in New Zealand?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: New Zealand Patent 582,423

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in New Zealand?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: New Zealand Patent 582,423

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in New Zealand?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: New Zealand Patent 581,803

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in New Zealand?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: New Zealand Patent 581,081
Patent Title: SYNTHETIC DEOXYCHOLIC ACID (DCA) OR AN ESTER, HYDROXAMALE, OR HYDROXYAMIDE THEREOF

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can CARDAMYST (etripamil) generic drug versions launch in New Zealand?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: New Zealand Patent 582,033
Patent Title: SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can TWIRLA (ethinyl estradiol; levonorgestrel) generic drug versions launch in New Zealand?

Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: New Zealand Patent 582,565
Patent Title: DERMAL DELIVERY DEVICE WITH IN SITU SEAL

Drug Price Trends for TWIRLA
TWIRLA is a drug marketed by Agile. There are three patents protecting this drug. Two tentatively approved generics are ready to enter the market.

See drug price trends for TWIRLA.

The generic ingredient in TWIRLA is ethinyl estradiol; levonorgestrel. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in New Zealand?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: New Zealand Patent 583,186
Patent Title: PYRIMIDINYL-PYRIDAZINONE DERIVATIVES

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in New Zealand?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: New Zealand Patent 583,187
Patent Title: PYRIDAZINONE DERIVATIVES

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can WINLEVI (clascoterone) generic drug versions launch in New Zealand?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: New Zealand Patent 599,437
Patent Title: Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives.

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in New Zealand?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: New Zealand Patent 600,767
Patent Title: ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in New Zealand?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: New Zealand Patent 615,953
Patent Title: Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in New Zealand?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: New Zealand Patent 583,147
Patent Title: DEHYDROEPIANDROSTERONE COMPOSITIONS FOR TREATING MENOPAUSE

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in New Zealand?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: New Zealand Patent 598,270
Patent Title: DHEA COMPOSITIONS FOR TREATING MENOPAUSE

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in New Zealand?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: New Zealand Patent 583,931

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in New Zealand?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: New Zealand Patent 600,085

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in New Zealand?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: New Zealand Patent 574,514
Patent Title: Compositions, suitable for oral administration, comprising a triazolo [4, 5-d]pyrimidin derivate

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can VIZAMYL (flutemetamol f-18) generic drug versions launch in New Zealand?

Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 30, 2027
Generic Entry Controlled by: New Zealand Patent 583,616

VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

See drug price trends for VIZAMYL.

The generic ingredient in VIZAMYL is flutemetamol f-18. Additional details are available on the flutemetamol f-18 profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in New Zealand?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: New Zealand Patent 583,899
Patent Title: PROCESS FOR THE MANUFACURE OF A PHARMACEUTICAL PRODUCT COMPRISING CITRIC ACID, MAGNESIUM OXIDE, POTASSIUM BICARBONATE AND SODIUM PICOSULFATE, PHARMACEUTICAL COMPOSITION COMPRISING GRANULES OBTAINED BY SUCH PROCESS AND INTERMEDIATE

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in New Zealand?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: New Zealand Patent 585,435
Patent Title: PHARMACEUTICAL COMPOSITIONS COMPRISING IRON OXY-HYDROXIDE

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in New Zealand?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: New Zealand Patent 590,601
Patent Title: PYRIMIDINE COMPOUNDS ESPECIALLY 4-PHENYLAMINO-2-ARYLAMINO-PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in New Zealand?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: New Zealand Patent 577,342
Patent Title: SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in New Zealand?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: New Zealand Patent 599,889
Patent Title: Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in New Zealand?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: New Zealand Patent 614,151
Patent Title: Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in New Zealand?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: New Zealand Patent 702,159
Patent Title: Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in New Zealand?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: New Zealand Patent 586,221
Patent Title: Dosing regimen associated with long acting injectable paliperidone esters

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can RYTARY (carbidopa; levodopa) generic drug versions launch in New Zealand?

Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 28, 2027
Generic Entry Controlled by: New Zealand Patent 586,870
Patent Title: Controlled release formulations of levodopa, carbidopa andd a caboxylic acid

RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering RYTARY

See drug price trends for RYTARY.

The generic ingredient in RYTARY is carbidopa; levodopa. Additional details are available on the carbidopa; levodopa profile page.

When can RYTARY (carbidopa; levodopa) generic drug versions launch in New Zealand?

Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 28, 2027
Generic Entry Controlled by: New Zealand Patent 602,302
Patent Title: Controlled release formulations of levodopa and uses thereof

RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering RYTARY

See drug price trends for RYTARY.

The generic ingredient in RYTARY is carbidopa; levodopa. Additional details are available on the carbidopa; levodopa profile page.

New Zealand Branded and Generic Drug Markets: Regulatory Opportunities, Patent Exposure, and Commercial Challenges

Last updated: October 11, 2026

New Zealand is a small, highly regulated pharmaceutical market in which public purchasing largely determines commercial access. The branded market offers opportunities in specialty medicines, hospital products, vaccines, and products with strong clinical differentiation. The generic market is more accessible from a regulatory standpoint but faces severe price competition, tender concentration, supply obligations, and limited market scale.

PHARMAC controls most publicly funded medicine purchasing and uses competitive tenders, reference pricing, sole-supply arrangements, and strict budget controls. Medsafe regulates medicine quality, safety, efficacy, approval, and monitoring. New Zealand has no U.S.-style Orange Book patent linkage system and no statutory Paragraph IV certification process. Patent disputes are generally separate from regulatory approval and public reimbursement.

How large is the New Zealand branded and generic drug market?

New Zealand has a small pharmaceutical market of approximately 5.3 million people. Public funding dominates demand, with PHARMAC and Health New Zealand acting as the principal institutional purchasers for funded medicines and hospital supply.

PHARMAC’s annual medicines expenditure is more than NZ$1.5 billion, although the figure includes different categories of medicines, vaccines, hospital products, and related supply arrangements depending on the reporting period (Pharmac, 2024). Private prescription sales, hospital procurement, and unfunded medicines form smaller commercial segments.

Market characteristic Commercial effect
Population of about 5.3 million Limited absolute volume and high launch-cost sensitivity
Public purchasing dominance Market access depends heavily on PHARMAC funding
Competitive tenders Rapid price erosion after generic entry
Sole-supply contracts Large volume opportunity for winners, but concentrated supply risk
English-language regulatory environment Relatively low documentation barriers for multinational companies
Geographic isolation Higher logistics, inventory, and shortage-management costs
No domestic pharmaceutical patent linkage Patent litigation is separate from approval and reimbursement

New Zealand is therefore less attractive as a standalone volume market than Australia, Japan, or major European countries. It can be commercially important as part of an Australia-New Zealand launch strategy, particularly for specialty medicines and products that use a common regional regulatory and distribution model.

What is the regulatory pathway for branded drugs in New Zealand?

Medsafe regulates medicines under the Medicines Act 1981 and Medicines Regulations 1984. A sponsor generally must obtain consent to distribute a new or changed medicine before commercial supply.

The principal regulatory categories are:

  1. New medicines.
  2. Changed medicines, including new strengths, formulations, indications, or manufacturing sites.
  3. Generic medicines.
  4. Biological medicines and biosimilars.
  5. Medical devices and borderline products subject to separate requirements.

Medsafe evaluates quality, safety, and efficacy. Product approval does not guarantee PHARMAC funding. A company can receive regulatory consent and still have no meaningful publicly funded market.

What FDA and European approvals mean in New Zealand

FDA, EMA, UK, Australian, and Canadian approvals can support the New Zealand dossier, but they do not automatically produce New Zealand approval. Medsafe may rely on overseas assessments, reference-country documentation, or abridged evidence in appropriate cases. The sponsor remains responsible for New Zealand labeling, pharmacovigilance, manufacturing compliance, and local obligations.

Medsafe participates in international regulatory cooperation, including work with the Australian Therapeutic Goods Administration and other regulators. International reliance can reduce duplication, but New Zealand-specific administrative and product information requirements remain relevant (Medsafe, 2024a).

What is the generic drug approval pathway in New Zealand?

Generic medicines generally rely on pharmaceutical equivalence, bioequivalence, quality data, and evidence supporting the proposed product. A generic sponsor does not normally need to repeat the originator’s full clinical development program.

The main regulatory opportunities are:

  • Entry after expiry or non-enforceability of relevant patents.
  • Approval through an abridged application.
  • Use of established active pharmaceutical ingredients.
  • Contract manufacturing and regional supply models.
  • Expansion into hospital and community pharmacy channels.
  • Product line extensions involving strengths, dosage forms, or pack sizes.

Generic approval is not the same as market access. PHARMAC may already have a funded supplier, a sole-supply agreement, or a reference price that makes entry commercially unattractive.

How does generic substitution work?

New Zealand allows substitution subject to regulatory, prescribing, pharmacy, and funding rules. Interchangeability is not determined solely by the sponsor’s commercial preference. Prescriber decisions, pharmacist obligations, funded-medicine rules, and product-specific restrictions can affect actual substitution.

Companies must therefore separate three questions:

  1. Can Medsafe approve the generic?
  2. Can the product be supplied legally?
  3. Can the product obtain funded volume at an acceptable margin?

The third question is often the most difficult.

What is the Orange Book status of New Zealand medicines?

New Zealand does not maintain a U.S.-style Orange Book that links approved medicines to patents and imposes automatic patent certifications on generic applicants.

Medsafe’s product information and medicine databases identify approved products, sponsors, active ingredients, and regulatory status. They do not operate as a comprehensive patent register for medicines. Patent information must generally be researched through the Intellectual Property Office of New Zealand, patent-owner disclosures, litigation records, and international patent-family analysis.

Issue United States New Zealand
Public patent listing tied to approved medicines Orange Book No equivalent comprehensive system
Paragraph IV certification Statutory pathway No direct equivalent
Automatic approval stay from patent litigation Available under Hatch-Waxman rules No equivalent automatic stay
Regulatory approval and patent rights Interlinked Generally separate
Patent validity and infringement forum Federal courts New Zealand courts under national patent law

This separation can reduce administrative barriers for generic applicants. It can also increase litigation uncertainty because patent status is less visible at the point of regulatory filing.

When do New Zealand drug patents expire?

New Zealand patents generally have a maximum term of 20 years from the filing date, subject to statutory requirements and transitional rules under the Patents Act 2013. New Zealand does not provide a broad U.S.-style patent term extension for regulatory delay in pharmaceutical approval.

Key patent categories include:

  • Compound or composition-of-matter patents.
  • Salt, polymorph, crystal, and stereoisomer patents.
  • Formulation and controlled-release patents.
  • Manufacturing-process patents.
  • Dosage-regimen patents.
  • Method-of-treatment or method-of-use patents.
  • Device and delivery-system patents.

A patent expiry date cannot be inferred from a global patent family alone. Applicants must check the New Zealand national phase, grant status, maintenance fees, terminal events, claim scope, and any applicable transitional provisions.

What formulations are protected by New Zealand patents?

Formulation patents can cover:

  • Extended-release tablets.
  • Long-acting injectables.
  • Microneedle or implant delivery systems.
  • Specific excipient combinations.
  • Stability-enhancing compositions.
  • Inhalation devices and dose-delivery systems.
  • Fixed-dose combinations.
  • Pediatric liquid formulations.
  • Container-closure systems with drug-release or stability functions.

Formulation protection can delay a direct generic formulation even when the active-ingredient patent has expired. It does not necessarily block every non-infringing generic product. Claim construction, product composition, manufacturing steps, and the scope of any method-of-use claims determine exposure.

Does New Zealand have Paragraph IV challenges?

New Zealand has no direct statutory equivalent to a U.S. Paragraph IV challenge. A generic company may seek regulatory approval and separately assess patent infringement or validity. It can challenge a patent through court proceedings or rely on a non-infringement position.

The commercial options are:

  1. Launch after patent expiry.
  2. Launch with a non-infringement position.
  3. Challenge validity before launch.
  4. Negotiate a license or supply arrangement.
  5. File for approval while managing litigation risk.
  6. Pursue a formulation or manufacturing route outside the patent claims.

This structure can enable earlier generic preparation but provides less predictable pre-launch patent clearance than the U.S. Hatch-Waxman system.

How strong is the patent estate for branded medicines in New Zealand?

Patent strength depends more on claim quality and remaining term than on the number of international family members. A practical New Zealand assessment should examine:

Patent issue Assessment question
Core compound patent Is the active ingredient protected in New Zealand?
Remaining term How many enforceable years remain?
Claim breadth Do claims cover the proposed generic product?
Formulation claims Does the generic use the protected dosage form?
Method-of-use claims Is the funded indication within the claim scope?
Process claims Is the generic manufacturing route exposed?
Patent status Is the patent granted, pending, expired, or lapsed?
Validity Are novelty, inventive step, sufficiency, or clarity vulnerabilities apparent?
Regulatory separation Can approval proceed despite the patent?
Commercial enforceability Would litigation be economically rational in New Zealand?

New Zealand’s small market can reduce the commercial incentive for a patent holder to litigate. It can also make a generic launch unattractive because expected revenue may not cover legal, inventory, and compliance costs.

What is the biosimilar opportunity in New Zealand?

Biosimilars are regulated as biological medicines and require a comparability-based evidence package. The assessment generally covers analytical similarity, manufacturing quality, pharmacokinetics, immunogenicity, and clinical evidence proportionate to the product and indication.

New Zealand is commercially attractive for biosimilars where:

  • The originator has high public expenditure.
  • Multiple brands can be funded.
  • PHARMAC can generate savings through tendering.
  • Hospital specialists accept the product.
  • Supply reliability is strong.
  • The biosimilar has approval in a trusted reference jurisdiction.

The main risk is that biosimilar approval does not guarantee automatic substitution or funding. PHARMAC determines procurement and reimbursement policy. Clinical switching, prescribing practice, and product-specific conditions can materially affect uptake.

What biosimilar risks affect originators?

Originators face:

  • Tender-driven price reductions.
  • Loss of sole-supply status.
  • Volume migration to lower-priced products.
  • Reduced negotiating leverage with PHARMAC.
  • Hospital-level adoption of alternative biologics.
  • Reimbursement decisions that favor the lowest-cost clinically acceptable option.

Unlike small-molecule generics, biosimilars may compete through price, supply assurance, manufacturing credibility, specialist confidence, and evidence on switching.

Which companies are challenging branded products in New Zealand?

Public information does not provide a complete centralized list of all New Zealand generic challengers. Competition usually comes from multinational and regional suppliers, including companies such as Viatris, Sandoz, Teva, Accord Healthcare, Apotex, Cipla, and Indian or Asian contract-manufacturing groups. Local distributors and New Zealand-registered sponsors can commercialize products manufactured overseas.

Competitive entry is often determined by PHARMAC procurement rather than by litigation. The effective challenger may therefore be the supplier that offers the lowest sustainable price with reliable delivery, not the first company to obtain regulatory approval.

What is the PHARMAC funding and procurement process?

PHARMAC evaluates medicines using clinical benefit, cost-effectiveness, total budget impact, health need, population effects, and availability of alternatives. Its Pharmaceutical Schedule determines which medicines are publicly funded and under what conditions.

Common commercial mechanisms include:

  • Sole-supply contracts.
  • Competitive tenders.
  • Reference pricing.
  • Special access or exceptional-access routes.
  • Hospital medicine procurement.
  • Supply guarantees.
  • Stockholding and distribution obligations.
  • Restrictions by indication, prescriber, or treatment line.

How do PHARMAC tenders affect generic margins?

Tenders can produce rapid uptake and predictable volume for the winning supplier. They can also create severe margin compression and dependence on a single contract.

A supplier should model:

  • Tender price and expected annual units.
  • Minimum supply commitments.
  • Inventory requirements.
  • Foreign-exchange exposure.
  • Freight and cold-chain cost.
  • Recall and shortage obligations.
  • Contract duration and renewal risk.
  • Competitor re-entry after the tender period.

A low tender price can be commercially viable only if volume is sufficiently large and supply costs are controlled.

What regulatory opportunities exist for pharmaceutical companies?

The strongest opportunities are concentrated in products with high clinical value or clear procurement benefits.

Branded medicine opportunities

  • Oncology and rare-disease products.
  • Vaccines and infectious-disease products.
  • Hospital medicines with limited competition.
  • Long-acting formulations.
  • Medicines that reduce administration or hospitalization costs.
  • Products addressing unmet Māori and Pacific health needs.
  • Specialty medicines with robust international evidence.

Generic and biosimilar opportunities

  • First generic entry after core patent expiry.
  • Products with a history of supply shortages.
  • Hospital products with few suppliers.
  • Biosimilars with established physician acceptance.
  • Differentiated pack sizes and dosage forms.
  • Products supported by reliable regional manufacturing.
  • Medicines that can compete in PHARMAC tenders.

What regulatory and commercial challenges affect market entry?

The main obstacles are:

  1. Small total market volume.
  2. Strong public-purchaser bargaining power.
  3. Low prices after tender competition.
  4. Concentrated distribution channels.
  5. Supply continuity obligations.
  6. Regulatory and reimbursement processes operating separately.
  7. Limited visibility of patent status through regulatory databases.
  8. Product shortages caused by global manufacturing disruption.
  9. Need for local pharmacovigilance and sponsor responsibilities.
  10. Political and policy changes affecting the future medicines framework.

New Zealand’s proposed transition from the Medicines Act framework to a replacement therapeutic-products regime creates regulatory planning risk. The Therapeutic Products Act 2023 was intended to establish a modern framework, but the government announced plans to repeal and replace it. Sponsors must monitor the transition because licensing, product approval, clinical-trial, and advertising requirements may change (Ministry of Health, 2024).

What patent litigation and settlement risks exist?

New Zealand patent litigation is usually less frequent than in the United States because the market is smaller and the absence of automatic approval stays reduces the commercial leverage of an originator.

Potential disputes include:

  • Infringement claims against a generic product.
  • Validity challenges to compound or formulation patents.
  • Judicial review of procurement decisions.
  • Contract disputes over PHARMAC supply terms.
  • Passing-off, trademark, or product-labeling disputes.
  • Confidentiality and manufacturing-process disputes.

Settlement agreements may include delayed entry, supply licenses, authorized-generic arrangements, or commercial terms tied to procurement. The public availability of detailed settlement terms is limited compared with U.S. Hatch-Waxman litigation.

How does New Zealand compare with Australia?

Australia offers a larger market and a more developed patent-litigation and reimbursement infrastructure. It also has the Pharmaceutical Benefits Scheme and the Therapeutic Goods Administration, while New Zealand relies on PHARMAC and Medsafe.

Factor New Zealand Australia
Market scale Smaller Larger
Public purchaser PHARMAC PBS and state hospital systems
Regulatory authority Medsafe TGA
Patent linkage No U.S.-style system Statutory notification and litigation mechanisms exist
Generic volume Limited Higher
Tender influence Very strong Significant but more fragmented
Commercial role Regional niche market Core Asia-Pacific market
Supply risk High due to geographic isolation Lower relative logistics risk

A New Zealand launch can follow an Australian strategy, but Australian approval, reimbursement, and patent outcomes do not automatically transfer.

What generic launch scenarios exist in New Zealand?

Scenario Likely outcome
Core patent expired and PHARMAC has no sole supplier Fastest entry opportunity
Core patent expired but formulation patent remains Product design and claim analysis required
Patent pending but approval available Regulatory entry may precede litigation
Originator has strong sole-supply position Approval may not generate volume
First generic wins tender High volume with low margin
Multiple generics enter simultaneously Rapid price compression
Biosimilar gains funding Gradual specialist-led uptake
Supply shortage affects originator Accelerated procurement opportunity
Small market with complex cold chain Entry may be commercially uneconomic

What licensing deals are relevant to the New Zealand market?

Licensing opportunities generally involve regional commercialization, distribution, manufacturing, or tender participation rather than New Zealand-only rights.

Potential structures include:

  • Australia-New Zealand commercialization licenses.
  • Exclusive distribution through a New Zealand sponsor.
  • Contract manufacturing for PHARMAC tenders.
  • Co-promotion of specialty products.
  • Biosimilar commercialization agreements.
  • Authorized-generic arrangements.
  • Technology licenses for formulation or delivery systems.
  • Supply agreements tied to hospital procurement.

A New Zealand-only license is often difficult to justify for a high-cost innovative medicine unless the product has a narrow specialist market or a significant public-funding opportunity.

Key Takeaways

  • New Zealand is a small pharmaceutical market dominated by public purchasing.
  • PHARMAC funding is usually more commercially important than Medsafe approval.
  • Generic entry is regulatorily accessible but economically difficult.
  • New Zealand has no comprehensive Orange Book and no direct Paragraph IV pathway.
  • Patent protection generally runs for up to 20 years from filing, without a broad pharmaceutical patent-term extension.
  • Formulation, manufacturing, dosage-regimen, and method-of-use patents can remain relevant after compound-patent expiry.
  • Biosimilar opportunities depend on PHARMAC funding, clinical acceptance, and supply reliability.
  • Sole-supply contracts can create large volume but increase concentration and continuity risk.
  • Australia-New Zealand regional strategies are more commercially attractive than New Zealand-only launches.
  • The replacement of the current therapeutic-products framework creates regulatory transition risk.

FAQs

Is Medsafe approval enough to sell a medicine in New Zealand?

No. Medsafe approval permits lawful supply, but commercial sales may require PHARMAC funding, hospital procurement, private prescribing, or a distribution arrangement.

Can a generic launch before a New Zealand patent expires?

Potentially. Regulatory approval and patent rights are generally separate. The sponsor must assess infringement, validity, and litigation exposure before launch.

Does New Zealand automatically substitute biosimilars for biologics?

No. Substitution and switching depend on regulatory status, clinical practice, funding rules, and PHARMAC procurement decisions.

Are New Zealand medicine patents listed in an Orange Book?

No. New Zealand does not maintain a U.S.-style Orange Book linking approved medicines to patents and generic certifications.

Is New Zealand an attractive first-launch market for an innovative drug?

Usually not as a standalone first-launch market. The strongest exceptions are products with high unmet need, limited competition, significant public-health value, or a coordinated Australia-New Zealand commercialization plan.

References

  1. Intellectual Property Office of New Zealand. (2013). Patents Act 2013. New Zealand Government.

  2. Medsafe. (2024a). New medicine applications and regulatory guidance. New Zealand Ministry of Health.

  3. Medsafe. (2024b). Data sheets, consumer medicine information, and medicine databases. New Zealand Ministry of Health.

  4. Ministry of Health. (2024). Therapeutic products regulatory reform. New Zealand Government.

  5. Pharmac. (2024). Annual report 2023/24. Pharmaceutical Management Agency of New Zealand.

  6. New Zealand Government. (1981). Medicines Act 1981. New Zealand legislation.

  7. New Zealand Government. (1984). Medicines Regulations 1984. New Zealand legislation.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.